Skip to main content
An official website of the United States government

Regorafenib

Placeholder slot
 (REH-goh-RA-feh-nib)

Regorafenib works by blocking proteins that signal cancer cells to divide. It also blocks proteins that signal the growth of new blood vessels that tumors need to grow. Blocking these signals keeps cancer cells from growing and spreading to other parts of the body. Regorafenib is a type of targeted therapy drug called a kinase inhibitor. It is a small-molecule drug (a drug that can enter cells easily).

US Brand Name(s)
Stivarga
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Regorafenib is approved to treat:

Regorafenib is also being studied in the treatment of other types of cancer.

More About Regorafenib

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Regorafenib - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Targeted Therapy to Treat Cancer

Clinical Trials Accepting Patients

Find Clinical Trials for Regorafenib - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated:
Email